Regulatory Insights
Field-tested guidance on peptide compliance, quality systems, and FDA expectations, covering the regulatory shifts, industry signals, and operational lessons shaping the peptide space right now.
-
The GLP-1 Peptide Crackdown: What Manufacturers Need to Know in 2025
The FDA’s intensified scrutiny of GLP-1 receptor agonist peptides — including semaglutide and tirzepatide — has reshaped the compliance landscape for manufacturers and compounding pharmacies. With demand skyrocketing and enforcement actions mounting, understanding the… Continue Reading
Current Peptide Compliance 